Article
Immunogenicity of constitutively active V599EBRaf.
Cancer research - 1 Aug 2004
Andersen Mads Hald, Fensterle Joachim, Ugurel Selma, Reker Sine, Houben Roland, Guldberg Per, Berger Thomas G, Schadendorf Dirk, Trefzer Uwe, Bröcker Eva-B, Straten Per thor, Rapp Ulf R, Becker Jürgen C
Abstract excerpt
Activating BRAF somatic missense mutations within the kinase domain are present in 60-66% of melanomas. The vast majority of these represent a single substitution of glutamate for valine (V599E). Here, we demonstrate spontaneous HLA-B*2705-restricted cytotoxic T-cell responses against an epitope derived from (V599E)BRaf. These T-cell responses were mutation specific as the corresponding epitope derived from...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.